12,110 Gilead Sciences, Inc. $GILD Shares Sold by CapWealth Advisors LLC

Key Points

• CapWealth Advisors reduced its Gilead Sciences stake by 5.2%, selling 12,110 shares and retaining 221,671 shares valued at approximately $33.0 million. Institutional investors and hedge funds collectively own 83.67% of the company.
• Analyst sentiment remains positive overall, with 23 Buy ratings and six Holds producing a “Moderate Buy” consensus and an average price target of $158.78, above the reported share price of $144.36.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year and above estimates, and maintains a quarterly dividend of $0.82 per share, equivalent to a 2.3% yield. Insiders sold 105,000 shares worth about $14.9 million during the latest quarter.

CapWealth Advisors LLC decreased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 5.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 221,671 shares of the biopharmaceutical company's stock after selling 12,110 shares during the quarter. Gilead Sciences accounts for about 2.5% of CapWealth Advisors LLC's portfolio, making the stock its 11th largest position. CapWealth Advisors LLC's holdings in Gilead Sciences were worth $33,040,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences in the fourth quarter valued at $25,000. Persistent Asset Partners Ltd acquired a new stake in Gilead Sciences during the 2nd quarter worth approximately $25,000. Kimelman & Baird LLC bought a new stake in shares of Gilead Sciences in the second quarter worth $25,000. Wealth Preservation Advisors LLC raised its position in Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Wiser Advisor Group LLC bought a new position in Gilead Sciences during the 2nd quarter worth $30,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada increased their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a "sector perform" rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research note on Saturday, September 19th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Truist Financial lowered their price objective on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a research report on Tuesday, July 7th. Finally, Zacks Research downgraded Gilead Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 29th. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $158.78.

Insider Transactions at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $144.22, for a total transaction of $432,660.00. Following the completion of the transaction, the insider directly owned 116,684 shares of the company's stock, valued at $16,828,166.48. This trade represents a 2.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares of the company's stock, valued at $1,916,306.28. This represents a 58.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 105,000 shares of company stock worth $14,940,540. Corporate insiders own 0.30% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded down $0.38 during mid-day trading on Monday, reaching $144.36. The company had a trading volume of 1,408,056 shares, compared to its average volume of 6,845,958. The company's 50-day moving average price is $143.63 and its 200-day moving average price is $136.49. Gilead Sciences, Inc. has a one year low of $112.41 and a one year high of $157.29. The firm has a market cap of $179.00 billion, a price-to-earnings ratio of -54.03 and a beta of 0.31. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.01 earnings per share. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were paid a dividend of $0.82 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Gilead Sciences Company Profile

Gilead Sciences, Inc NASDAQ: GILD is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead's portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.